DKSH (SIX:DKSH) is accelerating its life-science expansion: it struck a commercial partnership with Eli Lilly to distribute Lilly drugs in Hong Kong and Macau—building on ties in Singapore and Vietnam—while closing the acquisition of Italy’s Gale & Cosm to boost R&D and formulation capacity.
Previous Week Recap
- DKSH Partners With Lilly Hong Kong Macau: DKSH partners with Eli Lilly to commercialize, sell and distribute Lilly drugs in Hong Kong and Macau, expanding its existing Singapore and Vietnam tie-up and handling end-to-end commercialization.
- Gale & Cosm Acquisition Expands Italy: DKSH (DKSH) closed acquisition of Italy’s Gale & Cosm, expanding Performance Materials’ Life Science footprint in Italy and adding an innovation center and enhanced formulation labs.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.